Plain-English translation of NCT05502315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications: (a pill you take daily) and (an infusion you receive monthly). The study is designed for men with metastatic castration-resistant prostate cancer—meaning the cancer has spread to other parts of the body and is no longer responding to hormone therapy. Researchers want to see if these two medications working together can slow or stop the cancer's growth.
Men with advanced prostate cancer that stops responding to hormone therapy have limited treatment options, and outcomes can be poor. This trial is exploring whether combining these two medications—which work in different ways—might be more effective than using them separately or other current treatments.
You will have a baseline biopsy before starting treatment. Then you'll take as a daily oral pill and receive as an intravenous infusion once per month. Each treatment cycle lasts 28 days. You'll have blood tests (including PSA levels) once a month, imaging scans every 2 months for the first year and then every 3 months, and an on-treatment biopsy during your second cycle. You continue treatment as long as it's working and you're tolerating it well, with visits continuing until the cancer progresses or side effects become unmanageable.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States